6306-46-3

Usage

Uses

Used in Pharmaceutical Industry:
4,4'-(BromoMethylene)bis(chlorobenzene) is used as a chemical intermediate for the synthesis of pharmaceuticals, contributing to the development of new drugs and medicines.
Used in Agrochemical Industry:
In the agrochemical sector, 4,4'-(BromoMethylene)bis(chlorobenzene) serves as an intermediate, playing a crucial role in the production of agrochemicals that are vital for agricultural applications.
Used in Dye Industry:
4,4'-(BroMoMethylene)bis(chlorobenzene) is also utilized as an intermediate in the synthesis of dyes, which are essential for coloring fabrics, plastics, and other materials.
Used in Organic Electronic Materials:
4,4'-(BromoMethylene)bis(chlorobenzene) finds application in the production of organic electronic materials, which are increasingly important in the development of advanced electronic devices and technologies.
Used as a Reagent in Organic Synthesis:
Furthermore, it is employed as a reagent in organic synthesis, facilitating various chemical reactions and processes in the laboratory and industrial settings.
However, it is important to note that 4,4'-(BromoMethylene)bis(chlorobenzene) is considered a potential environmental contaminant and has been identified as a persistent organic pollutant. Therefore, it may pose health risks if not handled or disposed of properly. It is crucial to exercise caution and adhere to proper safety procedures when working with this chemical compound.

Upstream product

• 77-48-5 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione 
• 101-76-8 4,4'-dichlorodiphenylmethane 
• 58402-65-6 3-bromo-5,5-dimethylhydantoin 
• 90-97-1 4,4'-dichlorobenzophenone 
• 90-98-2 4,4'-Dichlorobenzophenone 
• 506-96-7 Acetyl bromide 
• 558-13-4 carbon tetrabromide 
• 106-39-8 bromochlorobenzene 
• 14774-78-8 4-chlorophenyl lithium 
• 104-88-1 4-chlorobenzaldehyde 

Downstream Products

• 78525-36-7 1,1,2,2-tetrakis(4-chlorophenyl)ethene 
• 102448-91-9 4',4''-Dichloro-3alpha-(diphenylmethoxy)tropane 
• 102476-03-9 4-(4,4'-dichloro-benzhydryloxy)-1,2,2,6-tetramethyl-piperidine 
• 39179-73-2 C₂₇H₂₀Cl₂ 
• 39479-29-3 C₃₁H₂₈Cl₂O₂ 
• 3480-85-1 (4,4'-Dichlor-benzhydryl)-thiocyanat 
• 120467-66-5 1,1-bis(p-chlorophenyl)-2-ethoxycarbonyl-5-methylhexan-3-one 
• 101859-52-3 C₂₃H₂₆Cl₂O 
• 93454-46-7 (4,4'-dichlorodiphenyl)methyl p-toluenethiosulfonate 
• 120467-68-7 2-[Bis-(4-chloro-phenyl)-methyl]-3-oxo-butyric acid ethyl ester 
• 120467-70-1 2-[Bis-(4-chloro-phenyl)-methyl]-3-oxo-hexanoic acid ethyl ester 
• 120467-69-8 2-[Bis-(4-chloro-phenyl)-methyl]-3-oxo-pentanoic acid ethyl ester 
• 57070-99-2 4,4'-dichlorobenzhydryl ethyl ether 
• 90-97-1 4,4'-dichlorobenzophenone 

Relevant academic research and scientific papers

SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS

Disclosed are compounds of Formula (I) or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Preparation method of aromatic nitrile compound or heteroaromatic nitrile compound

The invention discloses a preparation method of an aromatic nitrile compound or a heteroaromatic nitrile compound. The preparation method comprises: under the protection of an inert gas, in a solvent,under the actions of a nickel catalyst, a ligand, metal zinc and an additive, carrying out a reaction on a cyanation reagent and halogenated aromatic hydrocarbon or halogenated heteroaromatic hydrocarbon. According to the present invention, by using the inexpensive and easily-available nickel catalyst and the ligand, the halogenated aromatic hydrocarbon or halogenated heteroaromatic hydrocarbon,especially the chlorinated aromatic hydrocarbon or chlorinated heteroaromatic hydrocarbon with characteristics of low price, easy obtaining and low reaction activity can mildly and efficiently react with the cyanation reagent with low toxicity to prepare the aromatic nitrile compound or heteroaromatic nitrile compound; and the preparation method has advantages of simple operation, mildness, high efficiency and the like, and further has characteristics of good functional group compatibility, good universality of substrate and the like.

General and Mild Nickel-Catalyzed Cyanation of Aryl/Heteroaryl Chlorides with Zn(CN)2: Key Roles of DMAP

A new and general nickel-catalyzed cyanation of hetero(aryl) chlorides using less toxic Zn(CN)2 as the cyanide source has been developed. The reaction relies on the use of inexpensive NiCl2·6H2O/dppf/Zn as the catalytic system and DMAP as the additive, allowing the cyanation to occur under mild reaction conditions (50-80 °C) with wide functional group tolerance. DMAP was found to be crucial for successful transformation, and the reaction likely proceeds via a Ni(0)/Ni(II) catalysis based on mechanistic studies. The method was also successfully extended to aryl bromides and aryl iodides.

One-pot synthesis of 1-iodoalkynes and trisubstituted alkenes from benzylic and allylic bromides

1-Iodoalkynes are formed in moderate to high yields from readily accessible benzylic and allylic alkyl bromides by a one-pot homologation/double elimination procedure with iodoform (CHI3). The developed conditions include facile purification and avoid the use of an excess of triphenylphosphine (PPh3), as described in classical Corey-Fuchs iodoalkynylation conditions. Replacing CHI3 with CHI2Cl allows the isolation of the corresponding gem-(Z)-chloro-(E)-iodoalkene in good yield and stereoselectivity. Moreover, the use of benzhydryl bromides as nucleophiles enables the synthesis of trisubstituted alkenes under similar reaction conditions.

N-heterocyclic carbene-catalyzed cross-coupling of aromatic aldehydes with activated alkyl halides

N-Heterocyclic carbene-catalyzed umpolung of aldehydes followed by their interception with diarylbromomethanes has been reported. This conceptually novel transition-metal-free cross-coupling of aldehydes with alkyl halides works well at low catalyst loadings and under mild reaction conditions leading to the formation of diaryl acetophenone derivatives in good yields. In addition, α-halo ketones and esters can also be used as aldehyde reaction partners.

Enantioselective catalytic α-alkylation of aldehydes via an S N1 pathway

Primary aminothiourea derivatives are shown to catalyze enantioselective alkylation of α-arylpriopionaldehdyes with diarylbromomethane. Evidence for a stepwise, S N1 mechanism in the substitution reaction induced by anion binding to the catalyst is provided by catalyst structure-activity studies, kinetic isotope effects, linear free-energy relationship studies, and competition experiments.

Synthesis and anticonvulsant activity of some cinnamylpiperazine derivatives

A series of cinnamylpiperazine derivatives was synthesized using different benzophenone as starting material. The structures of the compounds were proved by their IR, 1H-NMR spectroscopic data and mass spectra data. The anticonvulsant activities of these compounds were evaluated with maximal electroshock (MES) test and rotarod test with intraperitoneal injection on KunMing mice. Among all the flunarizine analogues, no one exhibited better anticonvulsant activity than flunarizine. Flunarizine (4i) exhibited anticonvulsant activity with ED50 of 38.1 mg/kg, TD50 of 164.3 mg/kg and PI of 4.3 through administration intraperitoneal, and with ED50 of 56.8 mg/kg, TD50 of 456.3 mg/kg and PI of 8.0 through oral administration.

Can one predict changes from SN1 to SN2 mechanisms?

The reactions of substituted benzhydryl bromides Ar2CHBr with primary and secondary amines in DMSO yield benzhydryl amines Ar 2CHNRR′, benzophenones Ar2CdO, and benzhydrols Ar2CHOH. Kinetic investigations at 20°C revealed the rate law -d[Ar2CHBr]/dt = (k1 + k2[HNRR′])[Ar 2CHBr], where the amine independent term k1 gave rise to the formation of Ar2CdO and Ar2CHOH and the amine-dependent term k2[HNRR′] was responsible for the formation of Ar2CHNRR′. Clear evidence for concomitant S N1 and SN2 processes was obtained. While the rate constants of the SN1 reactions correlate with Hammett's σ+ constants (ρ = -3.22), the second-order rate constants k2 for the SN2 reactions are not correlated with the electron releasing abilities of the substituents, indicating that the transition states of the SN2 reactions do not merge with the transition states of the SN1 reactions. The correlation equation log k 20°C = s(E + N), where nucleophiles are characterized by N and s and electrophiles are characterized by E (J. Am. Chem. Soc. 2001, 123, 9500-9512), was used to calculate the lifetimes of benzhydrylium ions in the presence of amines and DMSO. The change from SN1 to SN2 mechanism occurred close to the point where the calculated rate constant for the collapse of the benzhydrylium ions with the amines just reaches the vibrational limit; that is, the concerted SN2 mechanism was only followed when it was enforced by the lifetime of the intermediate. The nucleophile-specific parameters N and s needed for this analysis were determined by studying the kinetics of the reactions of a variety of amines with amino-substituted benzhydrylium tetrafluoroborates (Ar2CH+BF4-) of known electrophilicity E in DMSO. Analogously, the rates of the reactions of laser flash photolytically generated benzhydrylium ions Ar2CH + with DMSO in acetonitrile were employed to determine the nucleophile-specific parameters N and s of DMSO, and it is reported that DMSO is a significantly stronger O-nucleophile than water and ordinary alcohols.

PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Pyrimidinone Derivatives, compositions comprising a Pyrimidinone Derivative, and methods of using the Pyrimidinone Derivatives for treating or preventing obesity, diabetes, a metabolic disease, a cardiovascular disease or a disorder related to the activity of GPR119 in a patient.

Heterocycle-substituted 3-alkyl azetidine derivatives

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).